Recombinant Human Growth Hormone (somatropin): Ongoing Safety Review – Possible Increased Risk of Death

Audience: Pediatrics, Endocrinology [UPDATED 08/04/2011] FDA has determined that, at this time, the evidence regarding recombinant human growth hormone and increased risk of death is inconclusive. In its analysis of the SAGhE study, FDA identified…

Related posts:

1. Actos (pioglitazone): Ongoing Safety Review – Potential Increased Risk of Bladder Cancer Audience: Endocrinology, Family Practice, Urology [UPDATED 06/15/2011] Use of the diabetes...
2. Abacavir – Ongoing Safety Review: Possible Increased Risk of Heart Attack Audience: Infectious Disease including Ziagen, Trizivir, and Epzicom ISSUE: FDA...